Immutep reports 81.1% 12-month disease-free survival in Phase II soft tissue sarcoma trial
IMMP•Immutep reported 81.1% 12-month disease-free survival in its Phase II EFTISARC-NEO soft tissue sarcoma trial. A registration-directed trial is targeted for the second half of 2027, subject to several conditions.




